Much excitement has built in recent years on the new class of incretin drugs that include glucagon-like-peptide-1 inhibitors (single agonists such as semaglutide) and also dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonists (dual agonists such tirzepatide). Billions of dollars are now being poured into research to develop new anti-obesity medications that exhibit stronger effects while minimizing side-effect profiles.
This article was originally published on MedicalXpress.com
